hIL-15 NOG小鼠, hIL-15 NOG Mice - 维通利华

产品服务 > 实验动物模型 > 查找动物模型品系

hIL-15 NOG Mice

品系代码：

414

专业名称：

NOD.Cg-Prkdc^scidIL2rg^tm1SugTg(CMV-IL2/IL15)1-1Jic/JicCrl

小鼠,免疫缺陷模型免疫学,肿瘤学同类系,免疫缺陷

【CIEM正式授权】表达人源细胞因子IL-15

品系来源

应用特性

价格规格

应用文献

品系来源

hIL-15 NOG小鼠由日本中央实验动物研究所（CIEM）培育而成。CIEM Mamoru Ito实验室通过将CMV启动子控制的含有hIL-15 cDNA的DNA转基因载体（带有hIL-2信号肽）显微注射到NOD/ShiJic-Il2rg小鼠的受精卵中，构建出Founder品系。该Founder再与NOG小鼠回交，建立了稳定的hIL-15 NOG小鼠。

✈ 2020年，维通利华从CIEM引入该品系。

☑ 拓展阅读：hIL-15 NOG小鼠在γδ T细胞治疗研究中的应用案例

☑ 拓展阅读：NK细胞研发加速计划：看hIL-15 NOG小鼠推动细胞疗法新进展

☑ 研发加速计划：点击立即获取hIL-15 NOG优惠名额

应用特性

研究用途：

非常适用于抗体依赖性的NK细胞毒性（ADCC）研究。
可用于基于NK细胞的肿瘤免疫疗法研究。
可用于癌症、传染病、免疫学、再生医学、人类免疫系统移植等研究。

特性：

毛色：白化

除了NOG小鼠的特性外，还具备以下特性：

表达人源细胞因子IL-15。
与NOG小鼠相比，huHSC-CD34+移植hIL-15 NOG小鼠后，人的NK细胞重建率更高，但寿命相对缩短。
huHSC-CD34+移植hIL-15 NOG小鼠后产生的人源NK细胞，能够表达各种NK细胞受体，刺激后也能够产生颗粒酶A和穿孔素。
直接移植人外周血单个核细胞来源的CD56+NK细胞（huPBMC-NK），也会有NK细胞的重建及扩增。

价格规格

品系代码	品系名称	日/周龄	性别	VAF/SPF级	Elite/SPF级
414	hIL-15 NOG	1-8周	雌		1290

*以上规格与价格自2025年1月1日至2025年12月31日有效。

应用文献

hIL-15 NOG Publications

Authors	Year	Paper Title	Keywords
Odd L Gammelgaard, et al.	2024	Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis	Adoptive cell transfer therapy, Anti-PDL1, triple-negative breast cancer, MDA-MB-231
Émilie Degagné, et al.	2024	High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models	BCMA, allogenei CAR-T, GvHD
Shahryar Khoshtinat Nikkhoi, et al.	2024	Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice	bispecific killer cell engager, BiKE:E5C1, NK cell, HER-2+,
Lisa A. King, et al.	2024	Vd2 T-cell engagers bivalent for Vd2-TCR binding provide antitumor immunity and support robust Vg9Vd2 T-cell expansion	Vg9Vd2 T-cells, bispecific T-cell engager, single domain antibody, expansion, immunotherapy, cancer
Khoshtinat Nikkhoi S, et al.	2024	Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice	HER2, CD16a, BiKE:E5C1, ADCC, laNK92, NK
Jian‑Xin Cui, et al.	2023	L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis	NK cell, Gastric cancer, Tumor microenvironment, L-kynurenine, Ferroptosis
Jens Pahl, et al.	2023	AFM13 enhances the anti-tumor activity of AB-101 towards CD30+ tumors, conferring tumor growth control in vivo.	AFM13，AB-101，ADCC, NK, CD30/CD16A，Bispecific antibody
Sumin Jo, et al.	2022	Endowing universal CAR T-cell with immuneevasive properties using TALEN-gene editing
Rodolfo Gonzalez, et al.	2022	CB-020, an Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic CAR-NK Cell Therapy, Engineered for Enhanced Activity Against Solid Tumors	CAR-NK, iPSC-derived, cell therapy, ROR1
Caruso, Simona et al.	2022	Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia	CAR-NK, AML, CD123, cell therapy
Anna Bunin, et al.	2019	Human transgenic IL-15 NOG mice reconstituted with human NK cells as a model for NK cell depletion	NK cell engraftment, ADCC, lymphoma
Ikumi Katano, et al.	2020	Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse	ADCC, NK cell, humanized,
Eduardo Huarte, et al.	2021	Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models	NK cell, GvHD, JAK/STAT,
Jens Pahl, et al.	2021	AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies	BiAbs,CD16/EGFR, breast cancer, antibody-dependent cell-mediated cytotoxicity (ADCC), macrohphage-mediated antibody-dependent cellular phagocytosis (ADCP), Immuno-Oncology
Kevin R. Kipp, et al.	2021	BNZ-2, a dual specific IL15/IL21 inhibitor, rescues humanized NOG-IL15 transgenic mice from intestinal acute graft vs host disease without disrupting NK and CD8 T cell engraftment	IL15/IL21 inhibitor, GvHD, blood immunophenotyping, CD8+ T cell
Nina B. Horowitz, et al.	2021	Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies	innate lymphocyte cell (ILCs), NK cell, cancer immunotherapy, oncoimmunology, PDX, humanized
C.Rudulier, et al.	2020	In vivo Model Development for Genome-Edited T Cell Therapeutics	safety assessment, cell therapy
Paul Volden, et al.	2018	Cytokine-transgenic NOG mice engrafted with human peripheral blood cells support natural killer cell expansion	NK cell, cytotoxicity,
Ikumi Katano, et al.	2017	Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse	NK cell, ADCC, leukemia, K562, gastric cancer, HER-2, cell therapy, humanized
Ikumi Katano, et al.	2016	Human interleukin-15 transgenic NOG mice support the long-term maintenance of human mature NK cells from peripheral blood	NK cell, myelogenous leukemia, K562 basic data of HIL-15 NOG model